Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

Hitoshi Sakuraba, Mai Murata-Ohsawa, Ikuo Kawashima, Youichi Tajima, Masaharu Kotani, Toshio Ohshima, Yasunori Chiba, Minako Takashiba, Yoshifumi Jigami, Tomoko Fukushige, Tamotsu Kanzaki, Kohji Itoh

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

We compared two recombinant α-Galactosidases developed for enzyme replacement therapy for Fabry disease, agalsidase alfa and agalsidase beta, as to specific α-galactosidase activity, stability in plasma, mannose 6-phosphate (M6P) residue content, and effects on cultured human Fabry fibroblasts and Fabry mice. The specific enzyme activities of agalsidase alfa and agalsidase beta were 1.70 and 3.24 mmol h-1 mg protein -1, respectively, and there was no difference in stability in plasma between them. The M6P content of agalsidase beta (3.6 mol/mol protein) was higher than that of agalsidase alfa (1.3 mol/mol protein). The administration of both enzymes resulted in marked increases in α-galactosidase activity in cultured human Fabry fibroblasts, and Fabry mouse kidneys, heart, spleen and liver. However, the increase in enzyme activity in cultured fibroblasts, kidneys, heart and spleen was higher when agalsidase beta was used. An immunocytochemical analysis revealed that the incorporated recombinant enzyme degraded the globotriaosyl ceramide accumulated in cultured Fabry fibroblasts in a dose-dependent manner, with the effect being maintained for at least 7 days. Repeated administration of agalsidase beta apparently decreased the number of accumulated lamellar inclusion bodies in renal tubular cells of Fabry mice.

Original languageEnglish
Pages (from-to)180-188
Number of pages9
JournalJournal of Human Genetics
Volume51
Issue number3
DOIs
Publication statusPublished - 2006 Mar
Externally publishedYes

Fingerprint

Galactosidases
Fibroblasts
Enzymes
Kidney
Spleen
Enzyme Replacement Therapy
Fabry Disease
Proteins
Ceramides
Inclusion Bodies
agalsidase alfa
agalsidase beta
Liver
mannose-6-phosphate

Keywords

  • α-Galactosidase
  • Enzyme replacement therapy
  • Fabry disease
  • Fabry mouse
  • Globotriaosyl ceramide

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. / Sakuraba, Hitoshi; Murata-Ohsawa, Mai; Kawashima, Ikuo; Tajima, Youichi; Kotani, Masaharu; Ohshima, Toshio; Chiba, Yasunori; Takashiba, Minako; Jigami, Yoshifumi; Fukushige, Tomoko; Kanzaki, Tamotsu; Itoh, Kohji.

In: Journal of Human Genetics, Vol. 51, No. 3, 03.2006, p. 180-188.

Research output: Contribution to journalArticle

Sakuraba, H, Murata-Ohsawa, M, Kawashima, I, Tajima, Y, Kotani, M, Ohshima, T, Chiba, Y, Takashiba, M, Jigami, Y, Fukushige, T, Kanzaki, T & Itoh, K 2006, 'Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice', Journal of Human Genetics, vol. 51, no. 3, pp. 180-188. https://doi.org/10.1007/s10038-005-0342-9
Sakuraba, Hitoshi ; Murata-Ohsawa, Mai ; Kawashima, Ikuo ; Tajima, Youichi ; Kotani, Masaharu ; Ohshima, Toshio ; Chiba, Yasunori ; Takashiba, Minako ; Jigami, Yoshifumi ; Fukushige, Tomoko ; Kanzaki, Tamotsu ; Itoh, Kohji. / Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. In: Journal of Human Genetics. 2006 ; Vol. 51, No. 3. pp. 180-188.
@article{9fd1ed0d3c434222acf9ca7fb37c51a6,
title = "Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice",
abstract = "We compared two recombinant α-Galactosidases developed for enzyme replacement therapy for Fabry disease, agalsidase alfa and agalsidase beta, as to specific α-galactosidase activity, stability in plasma, mannose 6-phosphate (M6P) residue content, and effects on cultured human Fabry fibroblasts and Fabry mice. The specific enzyme activities of agalsidase alfa and agalsidase beta were 1.70 and 3.24 mmol h-1 mg protein -1, respectively, and there was no difference in stability in plasma between them. The M6P content of agalsidase beta (3.6 mol/mol protein) was higher than that of agalsidase alfa (1.3 mol/mol protein). The administration of both enzymes resulted in marked increases in α-galactosidase activity in cultured human Fabry fibroblasts, and Fabry mouse kidneys, heart, spleen and liver. However, the increase in enzyme activity in cultured fibroblasts, kidneys, heart and spleen was higher when agalsidase beta was used. An immunocytochemical analysis revealed that the incorporated recombinant enzyme degraded the globotriaosyl ceramide accumulated in cultured Fabry fibroblasts in a dose-dependent manner, with the effect being maintained for at least 7 days. Repeated administration of agalsidase beta apparently decreased the number of accumulated lamellar inclusion bodies in renal tubular cells of Fabry mice.",
keywords = "α-Galactosidase, Enzyme replacement therapy, Fabry disease, Fabry mouse, Globotriaosyl ceramide",
author = "Hitoshi Sakuraba and Mai Murata-Ohsawa and Ikuo Kawashima and Youichi Tajima and Masaharu Kotani and Toshio Ohshima and Yasunori Chiba and Minako Takashiba and Yoshifumi Jigami and Tomoko Fukushige and Tamotsu Kanzaki and Kohji Itoh",
year = "2006",
month = "3",
doi = "10.1007/s10038-005-0342-9",
language = "English",
volume = "51",
pages = "180--188",
journal = "Journal of Human Genetics",
issn = "1434-5161",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

AU - Sakuraba, Hitoshi

AU - Murata-Ohsawa, Mai

AU - Kawashima, Ikuo

AU - Tajima, Youichi

AU - Kotani, Masaharu

AU - Ohshima, Toshio

AU - Chiba, Yasunori

AU - Takashiba, Minako

AU - Jigami, Yoshifumi

AU - Fukushige, Tomoko

AU - Kanzaki, Tamotsu

AU - Itoh, Kohji

PY - 2006/3

Y1 - 2006/3

N2 - We compared two recombinant α-Galactosidases developed for enzyme replacement therapy for Fabry disease, agalsidase alfa and agalsidase beta, as to specific α-galactosidase activity, stability in plasma, mannose 6-phosphate (M6P) residue content, and effects on cultured human Fabry fibroblasts and Fabry mice. The specific enzyme activities of agalsidase alfa and agalsidase beta were 1.70 and 3.24 mmol h-1 mg protein -1, respectively, and there was no difference in stability in plasma between them. The M6P content of agalsidase beta (3.6 mol/mol protein) was higher than that of agalsidase alfa (1.3 mol/mol protein). The administration of both enzymes resulted in marked increases in α-galactosidase activity in cultured human Fabry fibroblasts, and Fabry mouse kidneys, heart, spleen and liver. However, the increase in enzyme activity in cultured fibroblasts, kidneys, heart and spleen was higher when agalsidase beta was used. An immunocytochemical analysis revealed that the incorporated recombinant enzyme degraded the globotriaosyl ceramide accumulated in cultured Fabry fibroblasts in a dose-dependent manner, with the effect being maintained for at least 7 days. Repeated administration of agalsidase beta apparently decreased the number of accumulated lamellar inclusion bodies in renal tubular cells of Fabry mice.

AB - We compared two recombinant α-Galactosidases developed for enzyme replacement therapy for Fabry disease, agalsidase alfa and agalsidase beta, as to specific α-galactosidase activity, stability in plasma, mannose 6-phosphate (M6P) residue content, and effects on cultured human Fabry fibroblasts and Fabry mice. The specific enzyme activities of agalsidase alfa and agalsidase beta were 1.70 and 3.24 mmol h-1 mg protein -1, respectively, and there was no difference in stability in plasma between them. The M6P content of agalsidase beta (3.6 mol/mol protein) was higher than that of agalsidase alfa (1.3 mol/mol protein). The administration of both enzymes resulted in marked increases in α-galactosidase activity in cultured human Fabry fibroblasts, and Fabry mouse kidneys, heart, spleen and liver. However, the increase in enzyme activity in cultured fibroblasts, kidneys, heart and spleen was higher when agalsidase beta was used. An immunocytochemical analysis revealed that the incorporated recombinant enzyme degraded the globotriaosyl ceramide accumulated in cultured Fabry fibroblasts in a dose-dependent manner, with the effect being maintained for at least 7 days. Repeated administration of agalsidase beta apparently decreased the number of accumulated lamellar inclusion bodies in renal tubular cells of Fabry mice.

KW - α-Galactosidase

KW - Enzyme replacement therapy

KW - Fabry disease

KW - Fabry mouse

KW - Globotriaosyl ceramide

UR - http://www.scopus.com/inward/record.url?scp=33645218156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645218156&partnerID=8YFLogxK

U2 - 10.1007/s10038-005-0342-9

DO - 10.1007/s10038-005-0342-9

M3 - Article

C2 - 16372133

AN - SCOPUS:33645218156

VL - 51

SP - 180

EP - 188

JO - Journal of Human Genetics

JF - Journal of Human Genetics

SN - 1434-5161

IS - 3

ER -